Actively Recruiting

Phase Not Applicable
Age: 2Months - 18Years
All Genders
ID06564740

Umbilical Cord Derived Mesenchymal Stem Cell Transplantation in Infants with Biliary Atresia: A Randomized Controlled Trial

Led by Necmi Kadıoğlu Hospital · Updated on 2024-09-19

64

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Biliary atresia (BA) is a serious condition causing chronic liver problems in infants and is a leading reason for pediatric liver transplants. The condition often leads to liver cirrhosis after surgery if untreated. This research evaluates how well Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy works for infants with BA through a multicenter randomized controlled trial, building on previous successes with stem cell treatments in adults and children. In this study, infants who have had the Kasai portoenterostomy surgery will be divided into two groups. One group will receive UC-MSC therapy administered twice through the hepatic artery: once after surgery and again six months later, at a dose of 1 million UC-MSCs per kilogram of body weight. The other group will continue with the standard BA treatments without receiving stem cells, serving as a control. Participants will be followed for two years with regular health evaluations including blood tests to measure liver enzymes and bilirubin levels, liver biopsies to assess cirrhosis, and monitoring for complications such as cholangitis. Researchers will track adverse events and other outcomes like the Pediatric End-Stage Liver Disease score, re-operation rates, and liver transplantation. This long-term follow-up aims to assess the safety and effects of UC-MSC therapy in these infants.

CONDITIONS

Brief Title

Stem Cell Applications in Biliary Atresia Patients

Who Can Participate

Age: 2Months - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Infants diagnosed with liver cirrhosis due to biliary atresia following Kasai's operation
  • Patients aged 2 months or older up to 18 years
  • Signs of cirrhosis after Kasai's operation, including hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices confirmed by endoscopy, and cirrhosis confirmed by liver biopsy
Not Eligible

You will not qualify if you...

  • Epilepsy
  • Neurological disorders
  • Coagulation disorders
  • Diabetes
  • Syndromic type biliary atresia
  • Allergies to anesthetic agents
  • Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys
  • Active infections
  • Severe psychiatric disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Participants will be evaluated to confirm diagnosis of biliary atresia and assess liver cirrhosis status following Kasai's operation.

Surgery

Duration - Day of surgery

Participants undergo Kasai portoenterostomy surgery to manage biliary atresia.

1 in-person surgical visit

Treatment

Duration - 6 months between transplantations with ongoing treatment during this period

Participants in the experimental group receive two UC-MSC transplantations via the hepatic artery: the first immediately post-surgery and the second 6 months later. Participants in the control group continue with standard treatments without stem cell transplantation.

2 transplantation visits plus ongoing monitoring visits as part of routine care

Follow-up

Duration - Up to 2 years

Participants are monitored for adverse events and liver function for up to 2 years after treatment to assess safety and efficacy of the stem cell therapy.

Regular follow-up visits over 2 years to monitor liver health and complications

Trial Site Locations

Total: 1 location

1

Esenyurt State Hospital

Istanbul, Istanbul, Turkey (Türkiye), 34340

Actively Recruiting

Loading map...

Research Team

M

Mustafa Azizoglu, MD, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Childhood Liver Disease Research Network (ChiLDReN): A Prosp...

Biliary Atresia

Actively Recruiting

16 locations

BILACO Trial: Biliary Atresia - a Severe Complex Congenital ...

Biliary Atresia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here